Association of a common genetic variant in RNASEL and prostate cancer susceptibility
Metrics: PDF 1120 views | HTML 3280 views | ?
Li Zuo1,*, Ke-Wei Ren5,*, Yu Bai1,*, Li-Feng Zhang1,*, Jian-Gang Zou1,*, Xi-Hu Qin2, Yuan-Yuan Mi3, Atsushi Okada4 and Takahiro Yasui4
1Department of Urology, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China
2Department of General Surgery, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical University, Changzhou 213003, China
3Department of Urology, Third Affiliated Hospital of Nantong University, Wuxi 214041, China
4Department of Nephrourology, Nagoya City University Graduate School of Medical Sciences, Aichi 4678601, Japan
5Department of Orthopedics, The Affiliated Jiangyin Hospital of Southeast University Medical School, Jiangyin 214400, China
*These authors have contributed equally to this work
Xi-Hu Qin, email: [email protected]
Keywords: RNASEL, polymorphism, prostate cancer, meta-analysis
Received: April 26, 2017 Accepted: August 07, 2017 Published: September 05, 2017
The RNASEL gene (2’, 5’-oligoisoadenylate synthetase-dependent) encodes a ribonuclease that plays a significant role in the apoptotic and antiviral activities of interferons. Various studies have used polymorphisms in the RNASEL gene to evaluate prostate cancer risk but studies that show an association between RNASEL Arg462Gln (1385G>A, R462Q, rs486907) polymorphism and prostate cancer risk are somewhat inconclusive. To assess the impact of RNASEL Arg462Gln polymorphism on prostate cancer risk, we conducted a meta-analysis of all available studies including 11,522 patients and 10,976 control subjects. The overall results indicated no positive association between the variant and prostate cancer risk. However, in a subgroup analysis by ethnicity, obvious associations were observed in Hispanic Caucasians for allelic contrast (OR = 1.18, 95% CI = 1.00 - 1.39, Pheterogeneity = 0.010), homozygote comparison (OR = 1.50, 95% CI = 1.02 – 2.20, Pheterogeneity = 0.001), and the recessive genetic model (OR = 1.44, 95% CI = 1.01 - 2.05, Pheterogeneity = 0.002) ; and in African descendants for homozygote comparison (OR = 2.59, 95% CI = 1.29 – 5.19, Pheterogeneity = 0.194) and the recessive genetic model (OR = 2.61, 95% CI = 1.30 – 5.23, Pheterogeneity = 0.195). In conclusion, the RNASEL Arg462Gln polymorphism may contribute to the risk of developing prostate cancer in African descendants and Hispanic Caucasians. Further larger and well-designed studies are warranted to evaluate this association in detail.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.